Edition:
Deutschland

Aradigm Corp (ARDM.OQ)

ARDM.OQ on NASDAQ Stock Exchange Capital Market

1.39USD
23 May 2018
Change (% chg)

$0.10 (+7.75%)
Prev Close
$1.29
Open
$1.35
Day's High
$1.45
Day's Low
$1.33
Volume
11,208
Avg. Vol
39,051
52-wk High
$7.26
52-wk Low
$1.04

ARDM.OQ

Chart for ARDM.OQ

About

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery... (more)

Buy/Sell

Sell Hold Buy
3.00 Mean rating from 1 analysts

Overall

Beta: 1.63
Market Cap(Mil.): $55.61
Shares Outstanding(Mil.): 15.11
Dividend: --
Yield (%): --

BRIEF-Aradigm Reports Q4 Loss Per Share Of $0.28

* ARADIGM ANNOUNCES FOURTH QUARTER 2017 AND FULL YEAR FINANCIAL RESULTS

BRIEF-Aradigm Submits Marketing Authorisation Application To EMA For EU Marketing Approval Of Linhaliq

* ARADIGM SUBMITS MARKETING AUTHORISATION APPLICATION (MAA) TO EMA FOR EU MARKETING APPROVAL OF LINHALIQ IN NON-CYSTIC FIBROSIS BRONCHIECTASIS Source text for Eikon: Further company coverage:

BRIEF-Aradigm Says Received Nasdaq Notice It Is No Longer In Compliance With Requirements

* ARADIGM- RECEIVED NASDAQ NOTICE THAT AS OF JOHN SIEBERT APPOINTMENT,NO LONGER IN COMPLIANCE WITH NASDAQ'S INDEPENDENT DIRECTOR,AUDIT COMMITTEE REQUIREMENTS

BRIEF-FDA Declines To Approve Aradigm's Drug Linhaliq

* ARADIGM RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR LINHALIQ NDA

BUZZ-Aradigm Corp: Ladenburg Thalmann cuts rating to 'neutral'

** Drug developer's shares plunge 42.7 pct to $1.96 premarket - top pct loser among all U.S.-listed stocks

BRIEF-Aradigm - FDA Advisory Committee Did Not Recommend Approval For Linhaliq

* ARADIGM REPORTS RESULTS OF FDA ADVISORY COMMITTEE MEETING ON LINHALIQ‍​

BRIEF-Boxer Capital Reports 5.9 Pct Passive Stake In Aradigm Corp As Of Nov 30

* BOXER CAPITAL LLC REPORTS 5.9 PERCENT PASSIVE STAKE IN ARADIGM CORP AS OF NOVEMBER 30 - SEC FILING Source text: (http://bit.ly/2BDnINX) Further company coverage:

BRIEF-Aradigm Announces FDA Advisory Committee Meeting For Linhaliq

* ARADIGM ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR LINHALIQ

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -1.01%
Rohstoffe -0.41%
Industrie -0.14%
Konjunktur abhängige Waren & Dienstleistungen +0.32%
Konjunktur unabhängige Waren & Dienstleistungen -0.57%
Finanzindustrie +0.11%
Pharma +0.74%
Technologie -0.31%
Telekommunikation +0.41%

Nachrichten aus der Wirtschaft

Photo

US-Industrie mit weniger Aufträgen

Washington Überraschend starker Auftragsschwund in der US-Industrie: Die Bestellungen für langlebige Güter - vom Toaster bis zum Flugzeug - fielen im April um 1,7 Prozent zum Vormonat, wie das Handelsministerium am Freitag in Washington mitteilte.